Detection of human pappilomavirus(HPV) in peripheral blood cells of HIV-1 positive pregnant women

Os papilomavírus humanos (HPV) estão associados a diversas lesões do trato anogenital, tanto malignas quanto benignas. A imunodeficiência, como a encontrada em pessoas portadoras de HIV é um fator de risco para infecções genitais por HPV e sua progressão para neoplasias intra-epiteliais e cânceres genitais. O objetivo do presente estudo foi avaliar através de técnicas de biologia molecular, a prevalência da presença de DNA-HPV no sangue periférico entre as gestantes HIV-1 positivo. Um total de 60 gestantes HIV-1 positivo com infecção cervical positivo por HPV e 50 gestantes HIV-1 positivo sem infecção cervical por HPV apresentavam resultados de pesquisa de HPV cervical pelos métodos moleculares (Captura Híbrida-II e PCR/RFLP) e contagem de células CD4+ e carga viral do HIV-1 do plasma. As amostras disponíveis de sangue periférico das gestantes selecionadas foram submetidas à Nested-PCR seguido de sequenciamento para a pesquisa de DNA-HPV. A DNA-HPV foi detectado em 25,0% das gestantes HIV-1 positivo com infecção cervical por HPV e 4,0% das gestantes HIV-1 positivo sem infecção cervical por HPV (p=0,002). Nível de células CD4+ ≤ 200 células/mm3 , presença de infecção cervical por HPV com alta carga viral (> 200 RLU) são preditivo de uma maior probabilidade de presença de DNA-HPV no sangue periférico. Estes dados evidenciam a presença do DNA-HPV no sangue periférico. A presença do genoma de HPV em sangue periférico ainda é controversa e deve ser melhor estudada para que possa ser relacionada com o desenvolvimento de lesões malignas.Papilomavírus human (HPV) are associated with several lesions of the anogenital tract and are present in a variety of both malignant and benign lesions. The imunodeficiency, as the found one in carrying people of HIV is a factor of risk for genital infections for genital HPV and its progression for intra-epithelial neoplasias and cancers. The objective of the present study was to evaluate through techniques of molecular biology, the prevalence of the presence of DNA-HPV in the peripheral blood between the pregnant positive HIV-1 .A total of 60 pregnant positive HIV-1 with positive cervical infection for HPV and 50 pregnant positive HIV-1 without cervical infection for HPV presented resulted of cervical research of HPV for the molecular methods (Hybrid Capture II and PCR/RFLP) and counting of cells CD4+ and viral load of the HIV-1 of the plasma. The available samples of peripheral blood of the selected pregnant had been submitted to the followed Nested-PCR of sequenciamento for the research of DNA-HPV. The DNA-HPV was detected in 25,0% of pregnant positive HIV-1 with cervical infection for HPV and 4.0% of the pregnant positive HIV-1 without cervical infection for HPV (p=0,002). Level of cells CD4+ ≤ 200 células/mm3 , presence of cervical infection for HPV with high viral load (>200 RLU) are predict of a bigger probability of presence of DNA-HPV in the peripheral blood. The role of HPV viremia is controversial and warrants further investigation to determine its relationship with genital infection and whether there is a correlation with development of malignancies in HIV-infected individualsFundação de Amparo ao docente e ao Aluno (FADA)BV UNIFESP: Teses e dissertaçõe

Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis

Objective: To evaluate whether the quadrivalent human papillomavirus (HPV) (types 6, 11, 16, and 18) vaccine influences the clinical course of juvenile-onset recurrent respiratory papillomatosis (RRP) when administered to a group of patients with this condition. Methods: Uncontrolled intervention study of patients with juvenile-onset RRP examined at the Pediatric Otorhinolaryngology Clinic, Federal University of Sao Paulo, where nine patients between the ages of nine and 17 received three doses of the prophylactic quadrivalent HPV vaccine (Gardasil) and were followed for one year. Disease staging, intervals between relapses, intervals between surgeries, and the number of surgeries during the year prior to vaccination and during the first year after vaccination were compared. Results: Eight patients were infected with HPV-6 and one with HPV-11. There were no statistically significant differences in the clinical scores (p = 0.083), anatomical scores (p = 0.257), intervals between relapses (p = 0.062), intervals between surgeries (p = 0.357), or the numbers of surgeries (p = 0.180) when the years before and after vaccination were compared. All patients had relapses following vaccination. Conclusion: Patients with juvenile-onset RRP experienced a similar clinical course in the year after versus the year before vaccination with Gardasil. (C) 2016 Elsevier Ireland Ltd. All rights reserved.Univ Fed Sao Paulo, Discipline Pediat Otorhinolaryngol, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Pediat, Sao Paulo, BrazilRes Incent Fund Assoc, Sao Paulo, BrazilUniv Fed Sao Paulo, Discipline Infect Dis, Sao Paulo, BrazilUniv Fed Sao Paulo, Discipline Pediat Otorhinolaryngol, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Pediat, Sao Paulo, BrazilUniv Fed Sao Paulo, Discipline Infect Dis, Sao Paulo, BrazilWeb of Scienc